First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. - Wikidata - awgldk - TriplyDB

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

http://www.wikidata.org/entity/Q35636900

about

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis Comparison of performance of the Assessment of SpondyloArthritis International Society, the European Spondyloarthropathy Study Group and the modified New York criteria in a cohort of Chinese patients with spondyloarthritis Biologic agents in juvenile spondyloarthropathies Clinical Tools to Assess and Monitor Spondyloarthritis Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.Whole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis.Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis Incorporating assessment of the cervical facet joints in the modified Stoke ankylosing spondylitis spine score is of additional value in the evaluation of spinal radiographic outcome in ankylosing spondylitis.Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis.Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitors Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.Discovertebral (Andersson) lesions in severe ankylosing spondylitis: a study using MRI and conventional radiography.Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy.Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.Spondyloarthritides: evolving therapies A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitor The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis.Predicting the outcome of ankylosing spondylitis therapy Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study.Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.Association of single nucleotide polymorphism at position -308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis.ASAS/EULAR recommendations for the management of ankylosing spondylitis.Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial.Relationship between optimism and quality of life in patients with two chronic rheumatic diseases: axial spondyloarthritis and chronic low back pain: a cross sectional study of 288 patients.The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis.Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study.Bone formation rather than inflammation reflects ankylosing spondylitis activity on PET-CT: a pilot study Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.Early diagnosis of spondyloarthritis.Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).Tumour necrosis factor inhibitors in ankylosing spondylitis.Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.

P2860

Q24603648-26CAB530-BB55-4AD9-9FE0-9FB28D2E8DCC Q24604766-9AD18081-4A7F-4499-8610-EBBC27EDC1D6 Q26766263-143DCF05-7E88-451C-911E-53E7128D08A7 Q26866120-4A3637E3-C7AA-43C5-BA94-BD455BDF4963 Q28546596-0FB2C736-F2E5-42BC-855C-17F51FEAFA86 Q30413598-8DC260CA-4D00-40F2-A85E-1699432F92E2 Q33275865-C404D2C4-3913-4E47-AF38-4DC4A2BF5F22 Q33579196-23534EBB-E457-4679-946F-5B9C4246E8CA Q33604543-575F43B0-3CE4-448B-AC3B-5AE3AD3B06E2 Q33740351-51A1F1B9-18F6-4E97-A0AD-B9534AC99D2D Q33825162-DD2488AE-2952-4D27-9C72-21D1A7E87FE0 Q33923298-0359CD26-1621-4271-9A67-87475DE0FF31 Q34027624-AF9D1101-8269-42A3-91D4-79CBA15B27A9 Q34268747-E8274EC1-E6F0-441B-948A-63219ACD9FF0 Q34449888-A92DDC64-9CBF-44F4-AA5B-E84D1983CEBE Q34476049-5DB6D70A-F70C-49C3-862E-418A836DB746 Q34613907-075E67CF-B612-44F1-BE1D-E61410663FA0 Q34709566-8F9F8FB4-BE3F-44E7-95C1-6418C71A29F6 Q34774700-CAD60A04-8471-4EC6-A6C3-C9754DD58A19 Q34905433-E07426C5-B116-435A-B4DC-BDB34F96C7FA Q35449032-1EE367D9-5E92-4062-B28D-DD4CD0B606B4 Q35557916-1D156D30-C9D0-47C0-BCB1-CF7B7C567409 Q35614010-14D17C67-C913-459D-AB42-3BE2ADE966B6 Q35637012-C92C1DEB-8A68-4619-846C-1E8F30E9906C Q35637863-6095B8DD-C73D-477A-871B-1E4ED04A0AEE Q35819270-3E0F845A-029A-4F40-8F6D-FE197A2CEC50 Q35953515-4739C2F4-8313-4D78-BA9C-E78C00F5DB1B Q36009390-CF0E1B68-9A9A-4D4E-B94E-2895FBAD5EA2 Q36013849-93A2E25C-473F-4FCB-9F26-1CC0037427F7 Q36059338-FBF0587B-4BCA-4DC5-96F0-AB3AA7B8E909 Q36171750-96F4F766-8076-4F48-AD6C-BE1AC282F6F8 Q36204136-364FF993-9244-4381-B9A3-44AD5E9361C3 Q36245700-B82A3114-A2D3-45F4-8575-66904715BC46 Q36245785-84B2AF04-DC2D-411F-A36C-41C502F5A506 Q36458447-D028A9BB-A61F-4B05-8610-D188154559AB Q36477447-0ECEB8E5-D8C5-4D17-97F0-B88988FC5C4D Q36611042-D7BFDF9F-B7E7-4B51-98FE-F647C7ACDD25 Q36876679-CA345E04-C2A5-45AC-BDC9-97E427A69653 Q37142118-AC566C85-A04A-4884-A70D-9DA5A19A6396 Q37146227-F0E7AE1B-5132-49BE-AFDF-F0E066F9DFD3

P2860

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

http://www.wikidata.org/entity/Q35636900

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

First update of the internatio ...... s with ankylosing spondylitis.

@ast

First update of the internatio ...... s with ankylosing spondylitis.

@en

type

label

First update of the internatio ...... s with ankylosing spondylitis.

@ast

First update of the internatio ...... s with ankylosing spondylitis.

@en

prefLabel

First update of the internatio ...... s with ankylosing spondylitis.

@ast

First update of the internatio ...... s with ankylosing spondylitis.

@en

P1433

Q35636900-F7CC1133-83BC-429B-87F1-48C9AAA27483

P1476

Q35636900-16D4B3E9-C98C-435D-B31E-8A5931DAA72E

P2093

Q35636900-13D476B2-7F96-44B8-94B2-B81F0ED9D181

Q35636900-B224BBC7-1458-42D7-8464-57126749D41F

Q35636900-B8809E45-EF2F-40D7-913D-19464B24BE6A

Q35636900-BA6397BC-E3D6-418F-B068-AA716D086C5A

Q35636900-C5089530-2CC6-4266-8D60-EFA0FFA0A622

Q35636900-D1F09D3D-171F-482C-90E7-42F956DBC71D

P2860

Q35636900-19EBF63A-52EB-4450-974C-EA01E25CA21F

Q35636900-2054257F-BC0A-4856-AC0B-D0734A3DB869

Q35636900-2FA4B68B-AA44-4ED3-B1AE-EB3949F2EF83

Q35636900-307E0F23-B360-4B59-AC9E-22D0CD9DC87C

Q35636900-3447763E-BBFD-4B88-97C8-31E196610314

Q35636900-45ED10FB-29BD-4DD5-B271-565CF180374F

Q35636900-468AE591-5694-4B36-8A3B-7A789BBACAC0

Q35636900-4994C498-A5DB-483F-B7B6-1CC7F6C0A999

Q35636900-4EA2BC25-D02D-4A41-875D-EB4403659178

Q35636900-5846D840-06A9-462E-A870-7927561274FE

P304

Q35636900-D1D9D1FE-2569-4F65-BEA4-00C9835F8A41

P31

Q35636900-E3282686-4740-4F35-8A4D-5BB11BFF9657

P356

Q35636900-9734D0F5-B07E-4F05-B2E7-1557047C6511

P407

Q35636900-9B1F06FA-3164-4129-8CB0-FF6004A24770

P433

Q35636900-4DC9DC4D-15B2-4A9C-9258-C69AB84EB363

P478

Q35636900-BF0F9BA6-7ED2-440B-AC3C-436B75726CA5

P50

Q35636900-1FC91FAA-66B0-4E82-9EF1-3E5F30C7D72E

P577

Q35636900-DB890BAC-D605-46DB-BC04-2207B2BA3DAE

P5875

Q35636900-B4D6B6AE-9AF6-4345-AF39-3582A70C9A4D

P698

Q35636900-C1F7CA8D-B0E8-4B33-853B-A4F1D0F42018

P921

Q35636900-0E7B3508-2858-49E2-AF3B-66905885441C

Q35636900-9ABC6032-FF02-4915-AA97-542FA35266F5

Q35636900-F1CB5DC2-765B-43DE-8FD9-2368B7687503

P932

Q35636900-325EAD6A-9902-489A-BAFD-1A509B7108A6

P356

ARD.2005.040758

P1433

Annals of the Rheumatic Diseases

P1476

First update of the internatio ...... s with ankylosing spondylitis.

@en

P2093

ASAS Working Group

http://www.w3.org/2001/XMLSchema#string

J Braun

http://www.w3.org/2001/XMLSchema#string

J Davis

http://www.w3.org/2001/XMLSchema#string

J Sieper

http://www.w3.org/2001/XMLSchema#string

M Dougados

http://www.w3.org/2001/XMLSchema#string

S van der Linden

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

Infliximab maintenance therapy for fistulizing Crohn's disease

Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study.

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

P304

316-320

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2005.040758

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Désirée van der Heijde

P577

2005-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7664754

http://www.w3.org/2001/XMLSchema#string

P698

16096329

http://www.w3.org/2001/XMLSchema#string

P921

P932

1798064

http://www.w3.org/2001/XMLSchema#string